Duchenne muscular dystrophy (DMD) is a fatal genetic disorder characterized by skeletal muscle degeneration and cardiomyopathy. Effective cardiac therapies remain limited. This study investigated the therapeutic potential of the sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin (EMPA) in the dystrophin-deficient DBA2/J-mdx mouse model of DMD. Male mice received control chow or EMPA-containing chow (~25mg/kg/day), and cardiac function was evaluated longitudinally using four-dimensional ultrasound imaging. EMPA did not alter left ventricular mass or volume but delayed the onset of systolic dysfunction, preserving ejection fraction (EF) for 12 weeks and maintaining significantly higher EF through 24 weeks. EMPA also attenuated progressive impairments in systolic and diastolic myocardial deformation. Functional preservation was accompanied by reduced cardiomyocyte hypertrophy and reduced expression of cardiac stress genes. EMPA increased mtDNA copy number, reduced mtDNA damage, preserved the mtDNA-encoded respiratory chain protein MT-CO1, and increased myocardial ATP content, supporting improved mitochondrial integrity and myocardial energetic capacity. In addition, EMPA induced transcriptional changes consistent with enhanced fatty acid and ketone metabolism. Systemically, EMPA improved growth trajectory, preserved relative lean mass, increased skeletal muscle torque, attenuated fiber-type remodeling, and did not adversely affect renal function. Together, these findings support SGLT2 inhibitors as a promising therapeutic strategy for DMD-associated cardiomyopathy.
Benjamin J. Zeidler, Connor Thomas, John P. Salvas, Areli Jannes S. Javier, Alyssa M. Richards, Linda A. Bean, Conner C. Earl, Akanksha Agrawal, Niharika Narra, Steven N. Kozakiewicz, Lifan Zeng, Carol A Witczak, Joshua R Huot, Il-Man Kim, Meena S. Madhur, Mark C. Kowala, Larry W. Markham, Craig J. Goergen, Steven S. Welc
Usage data is cumulative from November 2026 through November 2026.
| Usage | JCI | PMC |
|---|---|---|
| Totals | 0 | 0 |
| Total Views | 0 | |
Usage information is collected from two different sources: this site (JCI) and Pubmed Central (PMC). JCI information (compiled daily) shows human readership based on methods we employ to screen out robotic usage. PMC information (aggregated monthly) is also similarly screened of robotic usage.
Various methods are used to distinguish robotic usage. For example, Google automatically scans articles to add to its search index and identifies itself as robotic; other services might not clearly identify themselves as robotic, or they are new or unknown as robotic. Because this activity can be misinterpreted as human readership, data may be re-processed periodically to reflect an improved understanding of robotic activity. Because of these factors, readers should consider usage information illustrative but subject to change.